CTOs on the Move

Perfect Health

www.perfecthealthinc.com

 
Perfect Health, an independent privately held company based in Cambridge, MA, is a full service primary care practice that sees seniors in their own homes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Perfect Health raised $25M on 09/03/2020

Similar Companies

DecisionHealth

DecisionHealth is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthQuest Physical Therapy

At HealthQuest Physical Therapy, our team of physical therapist provides personalized physical therapy treatment in Michigan. Schedule a free consult today!

EG Life Sciences

EG Life Sciences is a hybrid professional Life Sciences consulting services firm that provides Pharmaceutical, Biotechnology, and Medical device companies with the resources they need to meet the unique challenges of FDA regulated industries.

Westwood Health Care Ctr

Westwood Health Care Ctr is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.